David Alan Campbell Sells 5,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 5,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer now owns 293,054 shares of the company’s stock, valued at approximately $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 24th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00.
• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $67.00, for a total transaction of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $51.60, for a total transaction of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00.

Janux Therapeutics Stock Performance

JANX stock opened at $46.76 on Friday. The firm has a 50 day moving average price of $54.26 and a 200-day moving average price of $48.20. Janux Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $71.71. The firm has a market capitalization of $2.45 billion, a price-to-earnings ratio of -39.97 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics’s quarterly revenue was down 82.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in JANX. Amalgamated Bank increased its position in shares of Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares in the last quarter. Plato Investment Management Ltd bought a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after acquiring an additional 339 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $151,000. Finally, AQR Capital Management LLC bought a new stake in Janux Therapeutics in the 2nd quarter worth approximately $215,000. Institutional investors own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

JANX has been the subject of several research analyst reports. BTIG Research raised their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Stifel Nicolaus raised their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. HC Wainwright raised their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a report on Wednesday, December 11th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.